MedEx answers any queries you might have regarding Baraclude 0.5mg purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Baraclude 0,5 mg is a prescription drug, intended for the treatment chronic (long-lasting) hepatitis B virus in adult people and kids over the age of 2 age, suffering from active liver failure.
Baraclude falls within the group of medications called nucleoside analogs. It acts by reducing the amount of virus in the organism.
The medication was approved by the Food and Drug Administration for the treatment of HBV. Moreover, Baraclude 0,5 mg was approved for sale in such countries as Australia, India, Indonesia China, Singapore and Philippines.
In 2008, European Association for the Study of the Liver confirmed that Baraclude can be used as a first-line drug for the treatment of chronic hepatitis B.
How does this drug act?
Hepatitis B infection can caused liver damage. Baraclude decrease the amount of virus in your organism, and has been demonstrated to improve the liver function.
It is unknown whether Baraclude is safe for a long-term treatment.
It is important to remain under the medical supervision during and after Baraclude treatment. You should inform your doctors about any new symptoms, drugs or any other factors affecting your condition to your health care professional. Your disease may exacerbate if you stop using this drug. If your physician tells you to stop taking Baraclude, he/she will check your condition and do regular blood tests to control your liver function.
The common dosage of Baraclude is 0.5 mg (1 white pill) or 1 mg (1 pink pill) once a day.
If you suffer from any kidney disorder, your physician may adjust the frequency of use of Baraclude.
Way of use
The pill should be swallowed whole with a full glass of water. Take Baraclude before eating.
Serious acute exacerbations of hepatitis B have been reported in people who stopped anti-hepatitis B treatment, including Baraclude 0,5 mg. Liver function should be monitored carefully for about a few months after the end of hepatitis B treatment. If necessary, initiation of anti-hepatitis B treatment may be justified.
Limited clinical experience suggests there is a risk of developing resistance to HIV (human immunodeficiency virus) NRTIs if Baraclude 0,5 mg is used for the treatment of chronic hepatitis B in people with untreated HIV infection. Treatment with BARACLUDE is not advised for HIV/HBV co-infected patients using highly active antiretroviral therapy.